Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Pharma Confidence Surges in 2026; While Record M&A and IPO Activity Defy Geopolitical Pressure

Biopharmaceutical industry confidence reached a four-year high in early 2026, according to GlobalData’s State of the Biopharmaceutical Industry 2026 Mid-Year Update, based on a survey of 157 professionals. The report shows 55% of respondents are optimistic about growth despite geopolitical
  • News
Pharma Confidence Surges in 2026; While Record M&A and IPO Activity Defy Geopolitical Pressure

ICH Guidelines in 2026: QMS Integration, GMP Standards, and FDA EMA Harmonization

ICH Guidelines define a global framework for pharmaceutical quality, GMP compliance, and regulatory harmonization. This article explains how ICH Q8, Q9, Q10, and Q12 improve inspection readiness, strengthen quality systems, and align FDA and EMA expectations in practice.
  • Blog, Quality Management System
ICH Q8, Q9, Q10, and Q12 framework supporting Pharmaceutical Quality System, GMP Guidelines compliance, Quality Risk Management, and FDA inspection readiness.

Pharma Deal Slowdown Hits Q1 2026; As AI Partnerships Replace Traditional M&A Logic

Pharma dealmaking slowed in early 2026 as buyers tightened valuation discipline and increased diligence across life sciences transactions. AI partnerships, manufacturing acquisitions, and oncology consolidation are shaping the next phase of pharma deal activity, with recovery expected in late 2026
  • News
Pharma Deal Slowdown Hits Q1 2026; As AI Partnerships Replace Traditional M&A Logic

CNPV Promises Faster Drug Reviews; But Timeline Consistency Breaks

The Food and Drug Administration has introduced its Commissioner’s National Priority Voucher (CNPV) pilot program to accelerate drug and biologic review timelines in the United States. According to industry analysis by Lifescience Dynamics, the program aims to reduce approval timelines
  • News
CNPV Promises Faster Drug Reviews; But Timeline Consistency Breaks

FDA Shock U-Turn on mRNA-1010; From Rejection to Unanimous Vote

Pharmaceutical Executive Daily reports that the FDA Vaccines and Related Biological Products Advisory Committee unanimously voted 9–0 in favor of Moderna’s investigational mRNA-1010 seasonal influenza vaccine for adults aged 50–64 and 65+. The committee confirmed that the benefit-risk profile supports
  • News
FDA Shock U-Turn on mRNA-1010; From Rejection to Unanimous Vote

200 ADC Biotechs in China Raise Pressure on Daiichi Sankyo; as Global Oncology Race Intensifies

At ASCO 2026 in Chicago, Daiichi Sankyo R&D chief John Tsai outlined a long-term strategy to expand antibody-drug conjugate innovation using AI and data-driven biology. The company plans to build at least two new ADC platforms by 2030 while facing
  • News
200 ADC Biotechs in China Raise Pressure on Daiichi Sankyo; as Global Oncology Race Intensifies

FDA pharma regulations in 2026: GMP Enforcement, Inspection Rules, and Compliance Requirements

This article explains how FDA pharmaceutical regulations shape global GMP compliance, inspection outcomes, and enforcement actions. It explores FDA inspection findings, data integrity expectations, and evolving regulatory models that impact pharmaceutical quality systems and manufacturing standards worldwide.
  • Blog, Quality Management System
Pharmaceutical regulatory compliance visualization representing FDA GMP requirements for pharma companies, inspection findings, and drug manufacturing FDA regulations in a laboratory setting.

Cash Runway and Pipeline Cuts; The Warning Signs Behind Biopharma Layoffs

As layoffs continue across parts of the biopharma industry in 2026, experts say workforce reductions rarely happen without warning. While many employees focus on cost-cutting measures, industry leaders believe the strongest signals often come from clinical progress, pipeline strategy and
  • News
Cash Runway and Pipeline Cuts; The Warning Signs Behind Biopharma Layoffs